288 related articles for article (PubMed ID: 28800871)
1. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
Facchetti G; Petrella F; Spaggiari L; Rimoldi I
Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
[TBL] [Abstract][Full Text] [Related]
2. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
3. Novel platinum agents and mesenchymal stromal cells for thoracic malignancies: state of the art and future perspectives.
Petrella F; Rimoldi I; Facchetti G; Spaggiari L
Expert Opin Ther Pat; 2018 Nov; 28(11):813-821. PubMed ID: 30246568
[TBL] [Abstract][Full Text] [Related]
4. Combined hyaluronate-based films loaded with pemetrexed and cisplatin for the treatment of malignant pleural mesothelioma: Preliminary evaluation in an orthotopic tumor recurrence model.
Sonvico F; Barbieri S; Colombo P; Barocelli E; Mucchino C; Cantoni AM; Petronini PG; Rusca M; Carbognani P; Ampollini L
Eur J Pharm Sci; 2018 Oct; 123():89-97. PubMed ID: 30030099
[TBL] [Abstract][Full Text] [Related]
5. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
[TBL] [Abstract][Full Text] [Related]
6. Malignant pleural mesothelioma.
Chen SE; Pace MB
Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for immunotherapy in malignant pleural mesothelioma?
Tartarone A; Lerose R; Aieta M
Med Oncol; 2018 May; 35(7):98. PubMed ID: 29845408
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
9. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.
Ettinger DS; Wood DE; Akerley W; Bazhenova LA; Borghaei H; Camidge DR; Cheney RT; Chirieac LR; D'Amico TA; Dilling T; Dobelbower M; Govindan R; Hennon M; Horn L; Jahan TM; Komaki R; Lackner RP; Lanuti M; Lilenbaum R; Lin J; Loo BW; Martins R; Otterson GA; Patel JD; Pisters KM; Reckamp K; Riely GJ; Schild SE; Shapiro TA; Sharma N; Swanson SJ; Stevenson J; Tauer K; Yang SC; Gregory K; Hughes M
J Natl Compr Canc Netw; 2016 Jul; 14(7):825-36. PubMed ID: 27407123
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.
Petrella F; Coccè V; Masia C; Milani M; Salè EO; Alessandri G; Parati E; Sisto F; Pentimalli F; Brini AT; Pessina A; Spaggiari L
Biomed Pharmacother; 2017 Mar; 87():755-758. PubMed ID: 28153512
[TBL] [Abstract][Full Text] [Related]
11. [Malignant pleural mesothelioma: 2013 state of the art].
Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
[TBL] [Abstract][Full Text] [Related]
12. Pemetrexed Maintenance Therapy Following Bevacizumab-Containing First-Line Chemotherapy in Advanced Malignant Pleural Mesothelioma: A Case Report and Literatures Review.
Jing XQ; Zhou L; Sun XD; Yu JM; Meng X
Medicine (Baltimore); 2016 Apr; 95(14):e3351. PubMed ID: 27057918
[TBL] [Abstract][Full Text] [Related]
13. Updates in the diagnosis and treatment of malignant pleural mesothelioma.
Katzman D; Sterman DH
Curr Opin Pulm Med; 2018 Jul; 24(4):319-326. PubMed ID: 29553973
[TBL] [Abstract][Full Text] [Related]
14. Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.
Marcq E; Audenaerde JRV; Waele J; Jacobs J; Loenhout JV; Cavents G; Pauwels P; Meerbeeck JPV; Smits EL
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31455014
[TBL] [Abstract][Full Text] [Related]
15. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.
Salaroglio IC; Belisario DC; Bironzo P; Ananthanarayanan P; Ricci L; Digiovanni S; Fontana S; Napoli F; Sandri A; Facolmatà C; Libener R; Comunanza V; Grosso F; Gazzano E; Leo F; Taulli R; Bussolino F; Righi L; Papotti MG; Novello S; Scagliotti GV; Riganti C; Kopecka J
J Exp Clin Cancer Res; 2022 Feb; 41(1):75. PubMed ID: 35197103
[TBL] [Abstract][Full Text] [Related]
16. Clinical Response of Live-Attenuated,
Hassan R; Alley E; Kindler H; Antonia S; Jahan T; Honarmand S; Nair N; Whiting CC; Enstrom A; Lemmens E; Tsujikawa T; Kumar S; Choe G; Thomas A; McDougall K; Murphy AL; Jaffee E; Coussens LM; Brockstedt DG
Clin Cancer Res; 2019 Oct; 25(19):5787-5798. PubMed ID: 31263030
[TBL] [Abstract][Full Text] [Related]
17. Malignant pleural mesothelioma: an update on diagnosis and treatment options.
Kondola S; Manners D; Nowak AK
Ther Adv Respir Dis; 2016 Jun; 10(3):275-88. PubMed ID: 26873306
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.
Ceresoli GL; Bonomi M; Sauta MG
Expert Rev Anticancer Ther; 2016 Jul; 16(7):673-5. PubMed ID: 27224058
[No Abstract] [Full Text] [Related]
19. Advances in treatment of mesothelioma.
Maggioni C; Barletta G; Rijavec E; Biello F; Gualco E; Grossi F
Expert Opin Pharmacother; 2016 Jun; 17(9):1197-205. PubMed ID: 27055148
[TBL] [Abstract][Full Text] [Related]
20. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
